Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin + AVD for HIV-Associated Hodgkin Lymphoma
NCT01771107Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2013
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoints: Maximal Tolerated Dose of Brentuximab Vedotin at 28 days and Progression-free Survival at 2 years. Started Mar 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01771107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01771107.